Autoimmune antibody in a hemorrhagic patient interacts with thrombin- activated factor XIII in a unique manner

Blood

Volumn 93, Issue 3, 1999, Pages 909-917

  Lorand, Laszlo ^a   Velasco, Pauline T ^a   Murthy, S N Prasanna ^a   Lefebvre, Phil ^a   Green, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINOTRANSFERASE; AUTOANTIBODY; BLOOD CLOTTING FACTOR 13; CALCIUM ION; CASEIN; ENZYME PRECURSOR; IMMUNOGLOBULIN G; PUTRESCINE; THROMBIN; UREA;

ADULT; ARTICLE; BLEEDING DISORDER; BLOOD CLOT LYSIS; CASE REPORT; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVITY; FIBRIN FORMATION; HUMAN; HUMAN CELL; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

EID: 0032950953     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.3.909.403k17_909_917     Document Type: Article

References (41)

1. Lorand L: A study on the solubility of fibrin clots in urea. Hung Acta Physiol 1:192, 1948
2. Laki K, Lorand L: On the solubility of fibrin clots. Science 108:280, 1948
3. Lorand L: Contributions to the fibrinogen-fibrin problem (fibrin-stabilizing factor: FSF), in Proceedings of the International Society of Hematology. New York, NY, Grune & Stratton, 1950, p 407
4. Lorand L, Dickenman RC: Assay method for the "fibrin-stabilizing factor." Proc Soc Exp Biol 89:45, 1955
5. Lorand L, Konishi, K: Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys 105:58, 1964
6. Mann KG, Lorand L: Introduction to blood coagulation. Methods Enzymol 222:1, 1993
7. Lorand L, Jeong J-M, Radek JT, Wilson J: Human plasma factor XIII: Subunit interactions and activation of the zymogen. Methods Enzymol 222:22, 1993
8. Lorand L, Chenoweth D: Intramolecular localization of the acceptor cross-linking sites in fibrin. Proc Natl Acad Sci USA 63:1247, 1969
9. Schwartz ML, Pizzo SV, Hill RL, McKee PA: Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 248:1395, 1973
10. a. J Biol Chem 270:21827, 1995
11. a. Proc Natl Acad Sci USA 95:537,1998
12. Chen R, Doolittle RF: γ-γ Cross-linking sites in human and bovine fibrin. Biochemistry 10:4486, 1971
13. Doolittle RF, Chen R, Lau F: Hybrid fibrin: Proof of the intermolecular nature of γ-γ crosslinking units. Biochem Biophys Res Commun 44:94, 1971
14. Veklich Y, Ang EK, Lorand L, Weisel JW: The complementary aggregation sites of fibrin investigated through examination of polymers of fibrinogen with fragment E. Proc Natl Acad Sci USA 95:1438, 1998
15. Shen L, Lorand L: Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 71:1336, 1983
16. Bruner-Lorand J, Pilkington TRE, Lorand L: Inhibitors of fibrin cross-linking: Relevance for thrombolysis. Nature 210:1273, 1966
17. 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 65:290, 1980
18. 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 69:536, 1982
19. Lorand L: Fibrin clots. Nature 166:694, 1950
20. Lorand L, Urayama T, DeKiewiet JWC, Nossel HL: Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest 48:1054, 1969
21. Lorand L, Urayama T, Atencio AC, Hsia DY-Y: Inheritance of deficiency of fibrin-stabilizing factor (factor XIII). Am J Hum Genet 22:89, 1970
22. Lorand L, Losowsky MS, Miloszewski KJM: Human factor XIII: Fibrin stabilizing factor, in Spaet TH (ed): Progress in Hemostasis and Thrombosis, vol 5. New York, NY, Grune & Stratton, 1980, p 245
23. Ichinose A, Kaetsu H: Molecular approach to structure-function relationship of human coagulation factor XIII. Methods Enzymol 222:36, 1993
24. Mikkola H, Yee VC, Syrjälä M, Seitz R, Egbring R, Petrini P, Ljung R, Ingerslev J, Teller DC, Peltonen L, Palotie A: Four novel mutations in deficiency of coagulation factor XIII: Consequences to expression and structure of the A-subunit. Blood 87:141, 1996
25. Izumi T, Hashiguchi T, Castaman G, Tosetto A, Rodeghiero F, Girolami A, Ichinose A: Type I factor XIII deficiency is caused by a genetic defect of its b subunit: Insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood 87:2769, 1996
26. Lorand L: Acquired inhibitors of fibrin stabilization: A class of hemorrhagic disorders of diverse origins, in Green D (ed): Anticoagulants, Physiologic, Pathologic and Pharmacologic. Cleveland, OH, CRC, 1994, p 169
27. Green D, Velasco PT, Lorand L: Factor XIII autoantibody inhibiting α chain cross-linking of fibrin. Clin Res 40:242a, 1992 (abstr)
28. Green D, Sanders J, Wong C, Velasco PT, Lorand L: Coronary revascularization in the presence of an inhibitory antibody to factor XIII. Bull Intens Crit Care 3:14, 1996
29. Lorand L, Velasco PT, Rinne JR, Amare M, Miller LK, Zucker ML: Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci USA 85:232, 1988
30. Lin Y, Means GE, Feeney RE: The action of proteolytic enzymes on N,N-dimethyl proteins. Basis for a microassay for proteolytic enyzmes. J Biol Chem 244:789, 1969
31. Lorand L, Credo RB, Janus TJ: Factor XIII (fibrin stabilizing factor). Methods Enzymol 80:333, 1981
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193:265, 1951
33. Bishop PD, Teller DC, Smith RA, Lasser GW, Gilbert T, Seale RL: Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae. Biochemistry 29:1861, 1990
34. Lorand L, Campbell-Wilkes LK, Cooperstein L: A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem 50:623, 1972
35. Rosenberg RD, Colman RW, Lorand L: A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol 26:269, 1974
36. Moroi M, Inoue N, Yamasaki M: Analysis of the fibrin-polymerizing reaction using sodium dodecylsulfate-agarose gel electrophoresis. Biochim Biophys Acta 379:217, 1975
37. a. J Biol Chem 272:10311, 1997
38. Côté HCF, Pratt KP, Davie EW, Chung DW: The polymerization pocket "a" within the carboxyl-terminal region of the γ chain of human fibrinogen is adjacent to but independent from the calcium-binding site. J Biol Chem 272:23792, 1997
39. Curtis CG, Lorand L: Fibrin-stabilizing factor (factor XIII). Methods Enzymol 45:177, 1976
40. Mikkola H, Muszbek L, Laiho E, Syrjälä M, Hämäläinen E, Haramura G, Salmi T, Peltonen L, Palotie A: Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: A splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA. Blood 89:1279, 1997
41. Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger SM, Stern AM: Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: Mechanism of factor XIIIa inactivation. Biochemistry 33:10109, 1994